Zymeworks Inc. · NASDAQ:ZYME
Zymeworks — Technical Presentation (June 2018)
11 slides from Zymeworks's technical presentation, Jun 7, 2018
Slide 1: ZW25 – Bispecific for HER2-Expressing Cancers
CONFIDENTIAL ZW25 – Bispecific for HER2-Expressing Cancers HER2 HER2 Unique Mechanisms of Action Biparatopic - targets two distinct HER2 epitopes Increased tumor cell binding Potent effector-mediated cytotoxicity Blocks ligand-dependent and -independent tumor growth Enhanced HER2 internalization and
Slide 2: ZW25 – Adaptive Clinical Trial Design
CONFIDENTIAL ZW25 – Adaptive Clinical Trial Design Weekly and every two week dosing regimens evaluated Recommended dose and schedule: 10 mg/kg weekly or 20 mg/kg every two weeks Weekly ZW25 IV Days 1, 8, 15, and 22 of 28 day cycle 3+3 Dose Escalation (n=22) Every 2 Weeks ZW25 IV Days 1 and 15 of 28
Slide 3: ZW25 – Single Agent Anti-Tumor Activity in HER2-Expressing Cancer Patients
CONFIDENTIAL ZW25 – Single Agent Anti-Tumor Activity in HER2-Expressing Cancer Patients Target Lesions Decrease in Majority of Patients with Measurable Disease1 SLD = sum of longest diameters 111/42 patients not evaluable for change in SLD: too early (n=3); no target lesions (n=4); CNS progression o
Slide 4: Best RECIST 1.1 Response to Single Agent ZW25
CONFIDENTIAL Best RECIST 1.1 Response to Single Agent ZW25 DCR: Disease control rate = best response of stable disease or partial response at any time 1 Response evaluable = measurable disease per RECIST 1.1 and at least one tumor restaging or unequivocal clinical progression. Not evaluable n=9, inc
Slide 5: Breast Cancer: Single Agent Anti-tumor Activity
CONFIDENTIAL Breast Cancer: Single Agent Anti-tumor Activity SLD = sum of longest diameters . 3/20 breast cancer patients not evaluable for change in SLD: no measurable disease (n=2); clinical progression on Day 21 (n=1). 5 mg/kg QW 10 mg/kg QW 15 mg/kg QW 20 mg/kg Q2W % Change in SLD at Best Respon
Slide 6: Breast Cancer: Time on Treatment
CONFIDENTIAL Breast Cancer: Time on Treatment TPKL TPK TPKI TPKL TPK TPKL TPKLI TPKI TPK TPKLI TPKI TP TLK TPK TLK TPKL TPKI TLK TPKLI TPK 56 days = 2 cycles Days on Treatment T = trastuzumab; P = pertuzumab; K = T-DM1; L = lapatinib; I = investigational Breast Cancer Patients (n=20) 0 56 112 168 22
Slide 7: Gastric Cancer: Single Agent Anti-tumor Activity
CONFIDENTIAL Gastric Cancer: Single Agent Anti-tumor Activity Median 4 prior systemic regimens, including prior trastuzumab in all patients % Change in SLD at Best Response 5 mg/kg QW 10 mg/kg QW 15 mg/kg QW 20 mg/kg Q2W 5/13 patients GEA patients not evaluable for change in SLD: too early (n=1); no
Slide 8: Gastroesophageal Cancer: Time on Treatment
CONFIDENTIAL Gastroesophageal Cancer: Time on Treatment 56 days = 2 cycles Days on Treatment 0 56 112 168 224 280 HIGH HIGH HIGH HIGH HIGH INT LOW HIGH* HIGH LOW LOW HIGH HIGH HER2 Status1 Gastroesophageal Cancer Patients (n=13) 1 Discordance between local and central assessments; HER2 High status n
Slide 9: Other HER2 High Cancers: Single Agent Anti-tumor Activity
CONFIDENTIAL Other HER2 High Cancers: Single Agent Anti-tumor Activity All patients with history of HER2 High cancer Median 4 prior systemic regimens 0 56 112 168 Colorectal Colorectal Salivary Gallbladder Colorectal Cervical Adnexal Colorectal Colorectal Active Patients Days on Treatment 10 mg/kg Q
Slide 10: ZW25 – Data Highlights and Timeline
CONFIDENTIAL 2016 2017 2018 ZW25 – Data Highlights and Timeline Actively Recruiting for Parts 2 and 3: Single Agent and Combination Cohort Expansions Phase 1 Top- Line Data ASCO 2017 Dose Escalation 5;10;15 mg/kg weekly 20 mg/kg bi-weekly Single Agent Cohort Expansion Combination Tx Cohort Expansion
Slide 11: Incidence of HER2 Gene and Protein Expression in Various Cancers
CONFIDENTIAL Incidence of HER2 Gene and Protein Expression in Various Cancers Cancer Type Incidence of High HER2 Expression Gastroesophageal 4-22% Breast ~20% Bladder 5-15% Endometrial 8-35% Ovarian 6-7% Pancreatic 2-29% Cervical 1-21% Head & Neck 3% Colorectal 2-3% Lung 1-6% Melanoma 0-5% Excerpted